A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

which is critical for the effectiveness of the therapy. Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce fetal hemoglobin. The edited genes are infused into a patient ...

In December 2023, through the development efforts of CRISPR ... the gene that would hold the ticket: BCL11A. Sankaran and Orkin showed that BCL11A suppresses production of fetal hemoglobin.

Crispr Therapeutics AG reported ... specific enhancer region of the BCL11A gene. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells.

The company is in the very early stages of researching how to achieve an increase in fetal hemoglobin ... and Crispr Therapeutics, while Lyfgenia, made by Bluebird Bio, uses an older gene therapy ...